Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Q2 FY2016 Earnings Presentation
18 slides from Vivimed Labs's earnings presentation, Nov 10, 2015
Slide 1: Vivimed Labs Limited Q2 FY2016 Earnings Presentation
Vivimed Labs Limited Q2 FY2016 Earnings Presentation November 10, 2015© Vivimed Labs Ltd 2010 All rights reserved 1 www.vivimedlabs.com
Slide 2: Important Notice
Important Notice No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after
Slide 3: Vivimed Group Overview
Vivimed Group Overview A leading international brand in the Specialty Chemicals and Pharmaceuticals with global presence R&D Centres: Manufacturing Team Size 5 facilities +2,300 People R&D Team: 170+ personnel 12 (4 USFDA) Healthcare Specialty Chemicals • API 72.0% 28.0% • Personal Care • Contract F
Slide 4: Vivimed Group Overview
Vivimed Group Overview Preferred supplier to the leading global brands 4
Slide 5: Consolidated Financial Performance
Consolidated Financial Performance Performance Highlights: Q2 FY2016 vs. Q2 FY2015 Q2 FY2016 Revenue Breakup 4.1% Net Sales of Rs. 3,415 million 9.1% 72.0% o An increase of 7.8% 14.7% EBITDA of Rs. 632 million (up 22.0%) o EBITDA margin of 18.5%; significant improvement of 215 bps Net Profit o
Slide 6: Financial Performance
Financial Performance Consolidated Financials Q2 y-o-y Q1 q-o-q Half Year y-o-y Growth Growth Growth (Rs. million) FY2016 FY2015 FY2016 FY2016 FY2015 (%) (%) (%) Net Sales 3,415 3,168 7.8% 3,330 2.6% 6,745 6,846 (1.5)% EBITDA 632 518 22.0% 672 (6.0)% 1,304 1,099 18.7% Margin (%) 18.5% 16.3% 20.2% 19
Slide 7: Financial Performance: Management Perspectives
Financial Performance Q2 FY2016: Management Perspectives • Revenues increased by 7.8% to Rs. 3,415 million primarily due to the growth in the healthcare segment. This was partly offset by a decline in the Speciality Chemicals segment revenue during the quarter. o Healthcare revenues increased by 12.
Slide 8: Quarterly Financial Trends
Quarterly Financial Trends Net Sales EBITDA and Margins 3,567 3,447 3,415 672 3,330 3,168 632 603 Rs. Million Rs. Million 518 526 20.2% 17.5% 18.5% 16.3% 14.8% Q2 FY15 Q3 FY15 Q4 FY15 Q1 FY16 Q2 FY16 Q2 FY15 Q3 FY15 Q4 FY15 Q1 FY16 Q2 FY16 EBITDA Margin (%) Net Profit and Margins 242 239 206 Rs. Mil
Slide 9: Capital Markets
Capital Markets Shareholding Structure Key Institutional Investors 34.9% 37.0% 2.0% 26.1% Promoters FII DII Others Shareholding Pattern Trend Shareholders Sep-14 Dec-14 Mar-15 Jun-15 Sep-15 Promoters1 38.1% 38.1% 37.9% 37.0% 37.0% FII / FDI 27.7% 27.7% 27.7% 26.1% 26.1% DII 0.3% 0.1% 0.2% 1.6% 2.0%
Slide 10: Strategic Direction
Strategic Direction Continue to strengthen engagements with marquee customer base through superior product development and delivery capabilities Where Chemistry and Quality Matters Move up the value chain through vertical integration in Healthcare (R&D to manufacturing of API / FDF / brands) and tar
Slide 11: Global Reach
Global Reach A multinational global platform that provides Vivimed access to markets and significant cost advantage Kashipur, Uttarakhand Haridwar, Uttarakhand Sant Celoni, Spain Lliçà de Vall, Spain Kolkata Cuernavaca, Mexico Bonthapally, Hyderabad Bidar, Karnataka Bolarum, Hyderabad Jeedimetla, Hy
Slide 12: Strong Transnational Management Team
Strong Transnational Management Team Key Management Profile Dr. V Manohar Rao • Retired as joint director of The Veterinary Biological and Research Institute and has over 40 years of Chairman industry experience • Responsible for developing a sophisticated and well-equipped in-house quality control
Slide 13: Annexure – Consolidated Quarterly P&L Statement
Annexure – Consolidated Quarterly P&L Statement Profit & Loss Statement (Rs. million) Q2 FY15 Q3 FY15 Q4 FY15 Q1 FY16 Q2 FY16 Revenues Net Sales / Income from Operations (Net of Excise Duty) 3,136 3,437 3,562 3,315 3,370 Other Operating Income 32 10 5 14 45 Total Revenues 3,168 3,447 3,567 3,330 3,4
Slide 14: Annexure – Consolidated Segment Performance
Annexure – Consolidated Segment Performance Q2 y-o-y Q1 q-o-q Half Year y-o-y (Rs. million) FY2016 FY2015 Growth (%) FY2016 Growth (%) FY2016 FY2015 Growth (%) Segment Revenue 3,370 3,136 7.5% 3,315 1.7% 6,686 6,802 (1.7)% Specialty chemicals 943 987 (4.4)% 958 (1.5)% 1,901 1,873 1.5% Healthcare 2,4
Slide 15: Annexure – Consolidated Balance Sheet
Annexure – Consolidated Balance Sheet Liabilities (Rs. million) Mar-15 Sep-15 Assets (Rs. million) Mar-15 Sep-15 Shareholders funds Non current assets Share capital Tangible assets 6,963 6,925 Equity share capital 162 162 Intangible assets 1,172 1,013 Prefrence share capital 639 639 Tangible and Int
Slide 16: Annexure – Key Ratios
Annexure – Key Ratios FY2011 FY2012 FY2013 FY2014 FY2015 H1 FY16 Net Worth (Rs. million) 1,967 4,748 5,091 5,604 5,592 5,729 Net Debt (Rs. million) 2,959 5,279 6,414 8,591 9,852 10,290 Including current maturities of LT Debt Fixed Assets (Rs. million) 2,643 5,953 7,090 8,079 8,135 7,938 ROE (%) 24.8
Slide 17: Glossary
Glossary • ANDA: Abbreviated New Drug Application • API: Active Pharmaceutical Ingredients • CEP: Certificates of Suitability to the monographs of European Pharmacopoeia • CMO: Contract Manufacturing Organization • DMF: Drug Master File • FDF: Finished Dosage Formulation • H&PC: Home and Personal Ca
Slide 18: Thank You
Thank You Contact Details: Vivimed Labs Limited (CIN: L02411KA1988PLC009465) Veernag Towers, Habsiguda, Hyderabad 500 007 www.vivimedlabs.com Phone: +91 40 2717 6005 / 06 Fax: +91 40 2715 0599 Amarjeet Singh Bhatia +91 40 2717 6005 Vivimed Labs Limited Amarjit.Bhatia@vivimedlabs.com Saket Somani +91